Alternative Molecular Pathway in Transthyretin Amyloid Disease

Researchers at Scripps Research have uncovered an alternative molecular pathway for the unfolding of transthyretin (TTR), a protein implicated in the potentially fatal transthyretin amyloid disease (ATTR). Published on September 8, 2026, in the Proceedings of the National Academy of Sciences, the study demonstrates that certain TTR variants can bypass intermediate dimer pairs to unfold directly from tetramers into monomers under acidic conditions. This newly identified pathway raises questions about the effectiveness of existing treatments like tafamidis, which stabilizes the four-unit structure of TTR, especially for patients carrying rare hereditary variants associated with brain amyloid deposits. The authors emphasize that while the alternative route likely evolved for normal cellular protein recycling within acidic compartments like lysosomes, specific disease-associated mutations render this pathway accessible even at physiological blood acidity levels. This mechanistic insight suggests that certain rare genetic variants may lead to TTR aggregation in cerebrospinal fluid, potentially worsening patient outcomes under current standard therapies. Consequently, the findings prompt a reevaluation of drug discovery strategies targeting amyloidosis pathways. The research marks a significant milestone in structural biology as the first demonstration of pathway multiplicity in solution for an oligomeric protein without mechanical pulling. By combining cryogenic electron microscopy, X-ray crystal structures, and unfolding rate measurements across more than 100 TTR variants, the team successfully mapped the energy landscape governing protein denaturation. These insights provide a foundational framework for developing next-generation therapeutics tailored to specific misfolding mechanisms. Medical researchers and clinicians should utilize these findings to investigate whether alternative unfolding contributes to treatment resistance in rare ATTR cases. Further research is necessary to design targeted interventions capable of neutralizing both canonical and alternative pathways, ultimately improving clinical prognoses for patients with inherited amyloidosis disorders.